A surprisingly common liver disease affects millions in the US. What to know, according to a doctor

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.
Hosted on MSN

First enzyme-targeting drug reverses damage in metabolic fatty liver disease

Researchers at the University of California San Diego School of Medicine have identified a new investigational drug that shows promise in treating metabolic dysfunction-associated steatohepatitis ...
Healthline

What Causes Nonalcoholic Fatty Liver Disease?

Obesity, type 2 diabetes, and certain lifestyle habits can increase your risk of metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD, formally called nonalcoholic fatty liver ...

US FDA qualifies first AI tool to help speed liver disease drug development

The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a ...
IFLScience

First Targeted Treatment For Dangerous Liver Disease Could Come From An Unexpected Source

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
Becker's Hospital Review

FDA cleared 1st AI tool for liver disease trials

The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...